145343-76-6

Usage

Uses

Used in Pharmaceutical Industry:
2-Chloro-4-iodobenzoic acid is used as an intermediate in the synthesis of pharmaceuticals for its ability to be incorporated into various drug molecules, contributing to the development of new medications.
Used in Agrochemical Industry:
2-CHLORO-4-IODOBENZOIC ACID also serves as an intermediate in the synthesis of agrochemicals, playing a role in the production of pesticides and other agricultural chemicals to improve crop protection and yield.
Used in Dye and Pigment Production:
2-Chloro-4-iodobenzoic acid is utilized as a building block in the creation of dyes and pigments, providing a foundation for the development of colorants used in various industries, including textiles, plastics, and inks.
Used in Organic Synthesis:
Due to its reactivity, 2-chloro-4-iodobenzoic acid is a key component in the synthesis of other organic compounds, further expanding its applications across different chemical and industrial processes.

InChI:InChI=1/C7H4ClIO2/c8-6-3-4(9)1-2-5(6)7(10)11/h1-3H,(H,10,11)

Upstream product

• 2457-76-3 4-amino-2-chlorobenzoic acid 
• 27492-84-8 Methyl 4-amino-2-methoxybenzoate 

Downstream Products

• 860732-53-2 2-p-anisidino-4-iodo-benzoic acid 
• 104-94-9 4-methoxy-aniline 
• 158580-98-4 4-iodo-2-(N-methyl-N-methylsulphonyl)aminobenzoic acid 
• 156573-32-9 methyl 2-chloro-4-iodobenzoate 
• 1299483-30-9 2-Chloro-N-cyclopropyl-4-iodobenzamide 
• 1260654-93-0 (2-chloro-4-iodophenyl)methanol 
• 610-96-8 methyl chlorobenzoate 
• 1206599-46-3 2-chloro-4-iodo-1-(trifluoromethyl)benzene 
• 56363-84-9 2-chloro-4-hydroxybenzoic acid 
• 92712-69-1 ethyl 2-chloro-4-iodobenzoate 

Relevant academic research and scientific papers

Method for preparing iodo-benzoic acid (ester) by improving moral Michael reaction

The invention discloses a method for preparing iodo-benzoic acid (ester) by improving a moral reaction, and belongs to the technical field of organic synthesis. The method comprises the following steps: preparing and separating the diazonium tetrafluoroborate through diazotization of aminobenzoic acid (ester) and then performing iodination reaction with the iodinated reagent in an organic medium to obtain the corresponding iodo carboxylic acid (ester). The iodo-benzoic acid (ester) prepared by the method has high purity. The method has the advantages of good quality and simple post-treatment, and the product yield reaches 70 - 90%.

Vasopressin agonist formulation and process

This invention provides novel formulations for vasopressin agonist compounds, or a pharmaceutically acceptable salt thereof, having the general structure: and processes for making them, the formulations comprising from about 1% to about 20% of active ingredient, from about 1% to about 18% of a surfactant component, from about 50% to about 80% of a component of one or more polyethylene glycols, from about 1% to about 20% of a component of one or more sucrose fatty acid esters and/or polyvinylpyrrolidone and, optionally, one or more preservatives or antioxidants.

Tricyclic vasopressin agonists

This invention relates to new compounds selected from those of the general formula (I), or a pharmaceutically acceptable salt, ester or prodrug form thereof: wherein D, E and G are N or CH, which serve as vasopressin agonists and are useful in treating disorders such as diabetes insipidus, nocturnal enuresis, nocturia, urinary incontinence, bleeding and coagulation disorders, and the inability to temporarily delay urination and pharmaceutical compositions and methods for same.

RXR-agonist polycyclic aromatic compounds, pharmaceutical/cosmetic compositions comprising said compound and uses thereof

Novel pharmaceutically/cosmetically-active polycyclic aromatic compounds having the structural formula (I): wherein Ar is a radical having one of the formulae (a)-(e): which are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of mammalian skin and hair conditions/disorders are provided. In particular, based on their RXR-agonist activity, these compounds may be used to treat noninsulin-dependent diabetes mellitus (NIDDM) and obesity.

Polyaromatic propynyl compounds and pharmaceutical/cosmetic compositions comprised thereof

Novel pharmaceutically/cosmetically-active polyaromatic propynyl compounds have the structural formula (1): STR1 in which X is one of the radicals: STR2 and are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of mammalian skin and hair conditions/disorders.

Polycyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof

Novel pharmaceutically/cosmetically-active polycyclic aromatic compounds have the structural formula (I): STR1 wherein Ar is a radical having one of the formulae (a)-(i): STR2 and are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of mammalian skin and hair conditions/disorders.